Page 1 | Search Results | Blood | American Society of Hematology

1-9 of 9

Sort by

Sort Order Select

Journal Articles

A Phase 1b Study of Venetoclax (ABT-199/GDC-0199) in Combination with Decitabine or Azacitidine in Treatment-Naive Patients with Acute Myelogenous Leukemia Who Are ≥ to 65 Years and Not Eligible for Standard Induction Therapy

Courtney DiNardo, MD, Daniel Pollyea, MD MS, Keith Pratz, MD, Michael J. Thirman, MD, Anthony Letai, MD PhD, Mark Frattini, MD PhD, Brian Jonas, MDPhD, Joel Leverson, PhD, Ming Zhu, PhD, Martin Dunbar, DrPH, Nancy Falotico, Rachel Kirby, BA, Suresh Agarwal, PhD, Mack Mabry, MD, Jalaja Potluri, MD, Rod A. Humerickhouse, MD PhD, Hagop M. Kantarjian, MD, Marina Konopleva, MD PhD

Blood (2015) 126 (23): 327.

https://doi.org/10.1182/blood.V126.23.327.327

Published: 2015

Journal Articles

Mechanisms of Acquired Resistance to Venetoclax in Preclinical AML Models

Qi Zhang, Rongqing Pan, MS, Lina Han, PhD, Ce Shi, PhD, Stephen E. Kurtz, PhD, Hong Mu, MD PhD, Helen Ma, Michael Andreeff, MD PhD, Joel Leverson, PhD, Jeffrey W. Tyner, PhD, Yingchang Mi, MD PhD, Marina Konopleva, MD PhD

Blood (2015) 126 (23): 328.

https://doi.org/10.1182/blood.V126.23.328.328

Published: 2015

Journal Articles

Concomitantly Targeting BCL-2 with Venetoclax (ABT-199/GDC-0199) and MAPK Signaling with Cobimetinib (GDC-0973) in Acute Myeloid Leukemia Models

Lina Han, PhD, Qi Zhang, Ce Shi, PhD, Joel Leverson, PhD, Monique Dail, Darren C. Phillips, PhD, Jun Chen, MDPhD, Sha S Jin, Rodrigo Omar Jacamo, PhD, Naval Daver, MD, Elias J Jabbour, MD, Hagop M Kantarjian, MD, Michael Andreeff, MD PhD, Deepak Sampath, PhD, Marina Konopleva, MD PhD

Blood (2015) 126 (23): 2544.

https://doi.org/10.1182/blood.V126.23.2544.2544

Published: 2015

Journal Articles

Safety and Efficacy of Venetoclax (ABT-199/GDC-0199) Monotherapy for Relapsed/Refractory Multiple Myeloma: Phase 1 Preliminary Results

Blood (2015) 126 (23): 4219.

https://doi.org/10.1182/blood.V126.23.4219.4219

Published: 2015

Journal Articles

BCL-2 Inhibition By ABT-199 (Venetoclax/GDC-0199) and p53 Activation By RG7388 (Idasanutlin) Reciprocally Overcome Leukemia Apoptosis Resistance to Either Strategy Alone: Efficacy and Mechanisms

Rongqing Pan, MS, Vivian Ruvolo, MS, Hong Mu, MD PhD, Zhuanzhen Zheng, PhD, Joel Leverson, PhD, Kensuke Kojima, PhD, Marina Konopleva, MD PhD, Gwen Nichols, MD, Michael Andreeff, MD PhD

Blood (2015) 126 (23): 673.

https://doi.org/10.1182/blood.V126.23.673.673

Published: 2015

Journal Articles

Safety and Efficacy of Venetoclax (ABT-199/GDC-0199) in Combination with Bortezomib and Dexamethasone in Relapsed/Refractory Multiple Myeloma: Phase 1b Results

Philippe Moreau, MD PhD, Asher Chanan-Khan, MD, Andrew W. Roberts, MBBS, PhD, Amit B. Agarwal, MDPhD, Thierry Facon, Shaji Kumar, MD, Cyrille Touzeau, MD, David Darden, MS, Lura Morris, BA, Jeremy Ross, PhD, Ahmed H Salem, PhD, Wijith Munasinghe, PhD, Ming Zhu, PhD, Joel Leverson, PhD, Paulo Maciag, MD, Sari Heitner Enschede, MD, Maria Verdugo, MD, Rod A. Humerickhouse, MD PhD, Simon Harrison, MD

Blood (2015) 126 (23): 3038.

https://doi.org/10.1182/blood.V126.23.3038.3038

Published: 2015

Journal Articles

Cooperative Targeting of Bcl-2 Family Proteins By ABT-199 (GDC-0199) and Tyrosine Kinase Inhibitors to Eradicate Blast Crisis CML and CML Stem/Progenitor Cells

Bing Z Carter, PhD, Po Yee Mak, Hong Mu, MD PhD, Hongsheng Zhou, Duncan H Mak, M.S., Wendy D. Schober, MLT (ASCP), Joel Leverson, PhD, Bin Zhang, PhD, Ravi Bhatia, MD, Marina Konopleva, MD PhD, Jorge E. Cortes, Michael Andreeff, MD PhD

Blood (2014) 124 (21): 512.

https://doi.org/10.1182/blood.V124.21.512.512

Published: 2014

Journal Articles

Acute Lymphoblastic Leukemia Is a Bcl-2 Dependent Disease: Proteomic Profiling and Pre-Clinical Efficacy Of a Selective Bcl-2 Antagonist ABT-199

Blood (2013) 122 (21): 3919.

https://doi.org/10.1182/blood.V122.21.3919.3919

Published: 2013

Journal Articles

BCL-2-Selective BH3 Mimetic ABT-199 Is a Potent Agent For Acute Myeloid Leukemia

Rongqing Pan, MS, LaKeisha Debose, MS, Juliana M Benito, PhD, Leonard S Golfman, PhD, Patrick A Zweidler-McKay, MD, PhD, Lina Han, PhD, Karine G. Harutyunyan, PhD, Hong Mu, MD, PhD, Vivian R Ruvolo, MA, Eugene Park, Markus Muschen, MD, PhD, Joel Leverson, PhD, Gautam Borthakur, MD, Hagop M Kantarjian, MD, Peter P. Ruvolo, PhD, Michael Andreeff, MD, PhD, Marina Konopleva, MD, PhD

Blood (2013) 122 (21): 1456.

https://doi.org/10.1182/blood.V122.21.1456.1456

Published: 2013

NARROW

A Phase 1b Study of Venetoclax (ABT-199/GDC-0199) in Combination with Decitabine or Azacitidine in Treatment-Naive Patients with Acute Myelogenous Leukemia Who Are ≥ to 65 Years and Not Eligible for Standard Induction Therapy

Mechanisms of Acquired Resistance to Venetoclax in Preclinical AML Models

Concomitantly Targeting BCL-2 with Venetoclax (ABT-199/GDC-0199) and MAPK Signaling with Cobimetinib (GDC-0973) in Acute Myeloid Leukemia Models

Safety and Efficacy of Venetoclax (ABT-199/GDC-0199) Monotherapy for Relapsed/Refractory Multiple Myeloma: Phase 1 Preliminary Results

BCL-2 Inhibition By ABT-199 (Venetoclax/GDC-0199) and p53 Activation By RG7388 (Idasanutlin) Reciprocally Overcome Leukemia Apoptosis Resistance to Either Strategy Alone: Efficacy and Mechanisms

Safety and Efficacy of Venetoclax (ABT-199/GDC-0199) in Combination with Bortezomib and Dexamethasone in Relapsed/Refractory Multiple Myeloma: Phase 1b Results

Cooperative Targeting of Bcl-2 Family Proteins By ABT-199 (GDC-0199) and Tyrosine Kinase Inhibitors to Eradicate Blast Crisis CML and CML Stem/Progenitor Cells

Acute Lymphoblastic Leukemia Is a Bcl-2 Dependent Disease: Proteomic Profiling and Pre-Clinical Efficacy Of a Selective Bcl-2 Antagonist ABT-199

BCL-2-Selective BH3 Mimetic ABT-199 Is a Potent Agent For Acute Myeloid Leukemia

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only